We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

EFIRM Liquid Biopsy (eLB)

Webinar

 
EFIRM Liquid Biopsy (eLB)
 
David Wong
Director, Center for Oral/Head & Neck Oncology Research
 

The
advent of personalized medicine employing molecular targeted therapies
has markedly changed the treatment of cancer in the past decade. Liquid
biopsy is a rapidly emerging field to address this unmet clinical need
as diagnostics based on cell-free circulating tumor DNA (ctDNA) can be a
surrogate for the entire tumor genome.


We have developed a liquid biopsy technology “Electric Field Induced
Release and Measurement (EFIRM)- Liquid Biopsy (eLB)” provides the most
accurate targeted detection that can assist clinical treatment decisions
for the most common subtype of lung cancer, non-small cell lung cancer
(NSCLC), where tyrosine kinase inhibitors (TKI) that can extend the
disease progress free survival period of these patients.


Attend this webinar to learn:

  • Liquid biopsy for cancer detection
  • Electric field induced released and measurement (EFIRM)
  • Saliva as a sample type for liquid biopsy

 
 
 
 

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE